Wordt geladen...
Cardiotoxic effects of the novel approved anti-ErbB2 agents and reverse cardioprotective effects of ranolazine
PURPOSE: Pertuzumab, a novel anti-epidermal growth factor receptor 2 humanized monoclonal antibody, and trastuzumab-emtansine (TDM1), a novel antibody–drug conjugate made up of trastuzumab covalently linked to the highly potent microtubule inhibitory agent DM1, have been recently approved by the US...
Bewaard in:
| Gepubliceerd in: | Onco Targets Ther |
|---|---|
| Hoofdauteurs: | , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove Medical Press
2018
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5914739/ https://ncbi.nlm.nih.gov/pubmed/29719406 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S157294 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|